🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT06889363
Starting soon Phase 2

Clinical and Radiographic Evaluation of Indirect Pulp Capping Using Platelet Rich Fibrin Versus Mineral Trioxide Aggregate in Deep Carious Molars: a Randomized Controlled Trial

NCT06889363 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 2
Started
2025-06
Last updated
2025-03-21

Condition(s) studied

Dental CariesPulp CapingIndirect Pulp TreatmentIndirect Pulp CapIndirect Pulp CappingIndirect Pulp TherapyDeep Carious LesionDeep Carious LesionsMolar CariesCarious Molars

Investigational drug(s) / intervention(s)

MTAPRF

MTA: The indirect pulp capping will be applied using MTA using an MTA carrier, then glass ionomer will be applied, then composite restoration above

PRF: The indirect pulp capping will be applied using PRF on a membrane, then glass ionomer will be applied , then composite restoration above

Study summary

The aim of this study is the clinical and radiographic evaluation of (Platelet-Rich Fibrin (PRF) versus Mineral Trioxide Aggregate (MTA) in indirect pulp capping when used with deep carious molars over 1 year follow up.

Eligibility

Sex
ALL
Min age
20 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * o Patients with asymptomatic deep carious molars. * Patients with clinically and radiographically confirmed deep carious lesions that do not exhibit spontaneous pain. * Permanent molars only. * Teeth with intact or minimally restored occlusal surfaces (i.e., no extensive restorations or fractures). * No history of previous endodontic treatment or direct pulp capping on the study tooth. * No signs of periapical pathology based on radiographic evaluation. * Patients willing to participate and follow up for 12 months. * Patients who agree to return for scheduled follow-ups at 3, 6, and 12 months. Exclusion Criteria: * o Patients with systemic conditions affecting bone or tissue healing (e.g., uncontrolled diabetes, osteoporosis, immunosuppressed conditions). * Pregnant or lactating women (if applicable to your study). * Teeth with pulp exposure or necrotic pulp. * Presence of symptomatic irreversible pulpitis (e.g., spontaneous pain, lingering pain). * Periapical pathology or internal/external resorption detected radiographically. * Severely broken down or non-restorable teeth. * Calcified root canals or excessive sclerosis that could affect pulp testing reliability. * Any pre-existing root canal treatment on the selected tooth. * Patients who have undergone recent fluoride treatment, pulpotomy, or other pulp therapies in the past 6 months. * Patients using medications affecting bone and tissue regeneration (e.g., bisphosphonates, corticosteroids). * Patients unwilling or unable to commit to the 12-month follow-up schedule. * Patients with poor oral hygiene or high caries risk that could compromise treatment outcomes.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Cairo University Giza القاهرة - Cairo Governorate

More Cairo University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06889363 on ClinicalTrials.gov ↗ ← All trials in Egypt